New combo therapy aims to boost myeloma remission
NCT ID NCT07185477
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 21 times
Summary
This early-stage trial tests whether giving a bispecific antibody (GPRC5D/CD3) before CAR-T cell therapy can improve outcomes for adults with relapsed/refractory multiple myeloma, a blood cancer that has stopped responding to standard treatments. About 20 participants will receive the antibody first, then CAR-T cells, to see if this sequence leads to better tumor shrinkage and manageable side effects. The goal is to control the disease, not cure it, as ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.